{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-003717","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.983528+00:00","generated_at":"2026-05-16T06:55:53.558251+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors","bullets":["Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.","Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.","Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.","Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-003717","json":"https://secwatch.observer/filing/0001628280-26-003717.json","markdown":"https://secwatch.observer/filing/0001628280-26-003717.md","text":"https://secwatch.observer/filing/0001628280-26-003717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/0001628280-26-003717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026003717/pcrx-20260127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:55:53.558251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}